COVID-19 brought about major disruptions in many level of the economy and industrial companies were especially hard hit due to the turmoil that occurred in their supply chains as well as due to the recent significant increases in
their input costs.
Boston Scientific is no exception and inevitably was also impacted by the above-mentioned factors. As people opted to defer elective medical procedures, company sales plummeted in 2020 and the financial results of the Company were negatively impacted. In FY20, the company generated a negative $ 115 million (loss available to common stockholders). Click here to access the report